Previous findings indicated that miR-184 can inhibit the expression of SND1, MMP-2/9, CD44 in breast cancer and glioma, and act as a tumor inhibitor miRNA by inhibiting the expression of p53 and p21 and activity of caspase-3/8 in glioblastomas (29). This evidence concerns the gene CD44 and glioma.